AstraZeneca (AZN) Reports Q4 EPS of $1.30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AstraZeneca (AZN) PT Raised to $42 at Bernstein; 'Catalyst-Rich Year'
February 5, 2018 7:44 AM ESTBernstein raised its price target on AstraZeneca (NYSE: AZN) to $42.00 (from $40.00) while maintaining a Outperform rating.
Analyst Tim Anderson said both Q4 and guidance were decent and 2018 remains a catalyst-rich year.
... More